Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code

ZHANG Lifang, XU Lan. Cost-effectiveness analysis of community-acquired pneumonia therapeutic treatments[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(4): 315-317. doi: 10.3969/j.issn.1006-0111.2014.04.023
Citation: ZHANG Lifang, XU Lan. Cost-effectiveness analysis of community-acquired pneumonia therapeutic treatments[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(4): 315-317. doi: 10.3969/j.issn.1006-0111.2014.04.023

Cost-effectiveness analysis of community-acquired pneumonia therapeutic treatments

doi: 10.3969/j.issn.1006-0111.2014.04.023
  • Received Date: 2013-05-08
  • Rev Recd Date: 2013-11-12
  • Objective To evaluate the pharmacoeconomics effectiveness of two community-acquired pneumonia therapeutic treatments, and provide guidance for rational drug use. Methods Two therapeutic schemes were analyzed through cost-effectiveness analysis.Result Between the two treatments, the total cost by using moxifloxacin alone (Group A) was 4 092.75 RMB, while that of using azithromycin and cefuroxime (Group B) combined was 3 306.83 RMB; the effective rates were 88.89% and 85.71%, respectively; the incremental cost for each effect unit of these two treatments was 46.04 RMB and 38.58 RMB. Conclusion It is more economical and reasonable to use azithromycin and cefuroxime combination for the therapeutic treatment of community-acquired pneumonia.
  • [1] 吴袁剑云,英立平.临床路径实施手册[M].北京:北京医科大学出版社,2002:8.
    [2] 中华医学会呼吸病学分会.社区获得性肺炎诊断和治疗指南2006版[S].2006:5.
    [3] 中华人民共和国卫生部药政司.抗菌药物临床研究指导原则[S].北京:中华人民共和国卫生部,1993:2.
    [4] 丁玉峰,吴方建.药物经济学理论及应用[J].中国药师,2004,7(7):507-510.
    [5] 周玉清.三种胃溃疡伴幽门螺旋菌感染治疗方案的成本-效果分析[J].海峡药学,2003,15(2):73-74.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(2332) PDF downloads(79) Cited by()

Related
Proportional views

Cost-effectiveness analysis of community-acquired pneumonia therapeutic treatments

doi: 10.3969/j.issn.1006-0111.2014.04.023

Abstract: Objective To evaluate the pharmacoeconomics effectiveness of two community-acquired pneumonia therapeutic treatments, and provide guidance for rational drug use. Methods Two therapeutic schemes were analyzed through cost-effectiveness analysis.Result Between the two treatments, the total cost by using moxifloxacin alone (Group A) was 4 092.75 RMB, while that of using azithromycin and cefuroxime (Group B) combined was 3 306.83 RMB; the effective rates were 88.89% and 85.71%, respectively; the incremental cost for each effect unit of these two treatments was 46.04 RMB and 38.58 RMB. Conclusion It is more economical and reasonable to use azithromycin and cefuroxime combination for the therapeutic treatment of community-acquired pneumonia.

ZHANG Lifang, XU Lan. Cost-effectiveness analysis of community-acquired pneumonia therapeutic treatments[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(4): 315-317. doi: 10.3969/j.issn.1006-0111.2014.04.023
Citation: ZHANG Lifang, XU Lan. Cost-effectiveness analysis of community-acquired pneumonia therapeutic treatments[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(4): 315-317. doi: 10.3969/j.issn.1006-0111.2014.04.023
Reference (5)

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return